ZEISS VISUMAX 800 with SMILE pro software receives approval in China

Updated ZEISS femtosecond laser provides refractive surgeons in China with faster treatment, greater flexibility, and significant workflow 

JENA, Germany and SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the National Medical Products Administration (NMPA) in China has approved the VISUMAX^® 800 with SMILE^® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the China market at a time when more than 10 million eyes have been treated with ZEISS SMILE and SMILE pro worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia, Europe and the U.S.

ZEISS VISUMAX 800 with SMILE pro software

"With the growing interest in laser vision correction in China, the market needs innovative technology that enhances surgical outcomes, safety and efficiency to benefit both surgeons and their patients. The availability of the ZEISS VISUMAX 800 with SMILE pro software further extends our commitment to ophthalmologists and helps to solidify the future of laser vision correction across China," says Maximilian Foerst, Head of ZEISS Greater China.

"ZEISS further sets itself apart in the China market with the availability of the VISUMAX 800 with SMILE pro software from ZEISS, providing the latest digital technology to meet the evolving needs of refractive surgeons worldwide," said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "This next-generation femtosecond laser system creates data-driven insights to help surgeons better manage treatment paths for patients while supporting each surgeon's unique practice requirements for greater workflow efficiency and performance."

The VISUMAX^® 800 with SMILE^® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.^* Additionally, the shorter procedure time can reduce stress for surgeons and their patients. The ZEISS femtosecond laser also provides greater flexibility for the surgeon and patient, with a smaller footprint and compatibility with a variety of patient beds, adapting to the clinical environment to provide cutting-edge technology without compromise.

With the availability of the VISUMAX^® 800 with SMILE^® pro software from ZEISS in China, surgeons can utilize a number of workflow enhancements including: the CentraLign^® centration aid, a computer-controlled function for easy centration; the OcuLign^® cyclotorsion adjustment to help counter cyclotorsion that may occur; and VISULYZE user nomograms to help surgeons collect and analyze patient data, while also providing detailed nomograms and enabling more control during every surgery.

With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX^® 800 with SMILE^® pro software from ZEISS offers substantial market opportunities for surgeons in China. For more information about the VISUMAX^® 800 with SMILE^® pro software from ZEISS, visit https://zeiss.com/visumax800  

^* Data on file, myopia with optical zone 6.5 mm.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: [email protected]

Contact for the press
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: [email protected]

www.zeiss.com/newsroom